Rosarita Ferrara1, Valentina Ientile1, Vincenzo Arcoraci1,2, Carmen Ferrajolo3, Carlo Piccinni1,4, Andrea Fontana5, Salvatore Benvenga2, Gianluca Trifirò6,7. 1. Unit of Clinical Pharmacology, Academic Hospital G. Martino, Messina, Italy. 2. Department of Clinical and Experimental Medicine, University of Messina, Messina, Italy. 3. Department of Experimental Medicine, Second University of Naples, Naples, Italy. 4. Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy. 5. Unit of Biostatistics, IRCCS "Casa Sollievo della Sofferenza", San Giovanni Rotondo (FG), Italy. 6. Unit of Clinical Pharmacology, Academic Hospital G. Martino, Messina, Italy. trifirog@unime.it. 7. Department of Biomedical and Dental Sciences and Morpho-functional Imaging, University of Messina, Messina, Italy. trifirog@unime.it.
Abstract
BACKGROUND: Several conditions can modify the intestinal absorption of levothyroxine tablets, with potential consequences on their therapeutic effect. Pre-dosed ampoules and oral drops have been recently made available to overcome this limitation. AIMS: To describe the pattern of use of different formulations of levothyroxine in a general population of Southern Italy and to perform an exploratory analysis investigating the effect of switching from levothyroxine tablets to oral liquid formulations. METHODS: Data were extracted from the Caserta Local Health Unit database. All patients receiving at least one levothyroxine prescription during the years 2009-2015 were identified. 1-year incidence of use of formulation-specific levothyroxine was calculated. Switchers between levothyroxine tablets and oral liquid formulations were identified and the frequency of thyroid-stimulating hormone measurement within 2 years prior and after the switch date was explored. RESULTS: Overall, 56,354 levothyroxine users were included in the study. Of these, 55,147 patients received at least one prescription for tablets (97.9%), 1867 pre-dosed ampoules (3.3%) and 1550 oral drops (2.8%). The proportion of levothyroxine users receiving oral liquid formulations slightly increased over time. Patients switching from tablets to oral liquid formulations showed a statistically significant reduction in the number of thyroid-stimulating hormone measurements after switching from tablets, especially in presence of drugs interacting with levothyroxine potentially altering its absorption. CONCLUSIONS: Use of levothyroxine oral liquid formulations is increasing over time even though their use is still limited in a general population of Southern Italy. Our exploratory analysis showed that the frequency of thyroid-stimulating hormone measurement was reduced in patients switching from levothyroxine tablet to new formulations.
BACKGROUND: Several conditions can modify the intestinal absorption of levothyroxine tablets, with potential consequences on their therapeutic effect. Pre-dosed ampoules and oral drops have been recently made available to overcome this limitation. AIMS: To describe the pattern of use of different formulations of levothyroxine in a general population of Southern Italy and to perform an exploratory analysis investigating the effect of switching from levothyroxine tablets to oral liquid formulations. METHODS: Data were extracted from the Caserta Local Health Unit database. All patients receiving at least one levothyroxine prescription during the years 2009-2015 were identified. 1-year incidence of use of formulation-specific levothyroxine was calculated. Switchers between levothyroxine tablets and oral liquid formulations were identified and the frequency of thyroid-stimulating hormone measurement within 2 years prior and after the switch date was explored. RESULTS: Overall, 56,354 levothyroxine users were included in the study. Of these, 55,147 patients received at least one prescription for tablets (97.9%), 1867 pre-dosed ampoules (3.3%) and 1550 oral drops (2.8%). The proportion of levothyroxine users receiving oral liquid formulations slightly increased over time. Patients switching from tablets to oral liquid formulations showed a statistically significant reduction in the number of thyroid-stimulating hormone measurements after switching from tablets, especially in presence of drugs interacting with levothyroxine potentially altering its absorption. CONCLUSIONS: Use of levothyroxine oral liquid formulations is increasing over time even though their use is still limited in a general population of Southern Italy. Our exploratory analysis showed that the frequency of thyroid-stimulating hormone measurement was reduced in patients switching from levothyroxine tablet to new formulations.
Authors: G Ianiro; F Mangiola; T A Di Rienzo; S Bibbò; F Franceschi; A V Greco; A Gasbarrini Journal: Eur Rev Med Pharmacol Sci Date: 2014 Impact factor: 3.507
Authors: G Trifirò; M Alacqua; S Corrao; S Moretti; D U Tari; M Galdo; A P Caputi; V Arcoraci Journal: Eur J Clin Pharmacol Date: 2008-06 Impact factor: 2.953
Authors: I Pirola; E Gandossi; D Brancato; F Marini; A Cristiano; A Delbarba; B Agosti; M Castellano; C Cappelli Journal: J Endocrinol Invest Date: 2018-03-26 Impact factor: 4.256
Authors: Camilla Janett-Pellegri; Lea Wildisen; Martin Feller; Cinzia Del Giovane; Elisavet Moutzouri; Oliver Grolimund; Patrick Walter; Gérard Waeber; Pedro Marques-Vidal; Peter Vollenweider; Nicolas Rodondi Journal: PLoS One Date: 2021-12-20 Impact factor: 3.240